Figure 2.

Predicted change from baseline of log₁₀ colony‐forming unit (CFU)/lungs after mono and combination therapies based on the final Multistate Tuberculosis Pharmacometric‐General Pharmacodynamic Interaction model (solid lines) compared to model‐predicted expected additivity (dotted lines) after 10 mg/kg rifampicin monotherapy (R₁₀), 25 mg/kg isoniazid monotherapy (H₂₅), combination therapy of 10 mg/kg rifampicin and 25 mg/kg isoniazid (R₁₀H₂₅), combination therapy of 10 mg/kg rifampicin, 25 mg/kg isoniazid, and 150 mg/kg pyrazinamide (R₁₀H₂₅Z₁₅₀), combination therapy of 10 mg/kg rifampicin, 25 mg/kg isoniazid, 150 mg/kg pyrazinamide, and 100 mg/kg ethambutol (R₁₀H₂₅ Z₁₅₀E₁₀₀). Observed data are given as symbols. The data did not support any drug effect from pyrazinamide or ethambutol in monotherapy. The fluctuations in response are due to drug treatments in 5 of 7 days per week.